How Placebos Change the Patient's Brain

被引:280
作者
Benedetti, Fabrizio [1 ,2 ]
Carlino, Elisa [1 ,2 ]
Pollo, Antonella [1 ,2 ]
机构
[1] Univ Turin, Sch Med, Dept Neurosci, I-10125 Turin, Italy
[2] Natl Inst Neurosci, I-10125 Turin, Italy
关键词
placebo; nocebo; anxiety; reward; learning; genetics; INFERIOR PREFRONTAL CORTEX; ANTERIOR CINGULATE CORTEX; STRESS-INDUCED ANALGESIA; TRANSIENT ACTIVATION; INDUCED EXPECTATIONS; NOCEBO HYPERALGESIA; OPIOID ACTIVITY; PAIN; CHOLECYSTOKININ; ANTICIPATION;
D O I
10.1038/npp.2010.81
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Although placebos have long been considered a nuisance in clinical research, today they represent an active and productive field of research and, because of the involvement of many mechanisms, the study of the placebo effect can actually be viewed as a melting pot of concepts and ideas for neuroscience. Indeed, there exists not a single but many placebo effects, with different mechanisms and in different systems, medical conditions, and therapeutic interventions. For example, brain mechanisms of expectation, anxiety, and reward are all involved, as well as a variety of learning phenomena, such as Pavlovian conditioning, cognitive, and social learning. There is also some experimental evidence of different genetic variants in placebo responsiveness. The most productive models to better understand the neurobiology of the placebo effect are pain and Parkinson's disease. In these medical conditions, the neural networks that are involved have been identified: that is, the opioidergic-cholecystokinergic-dopaminergic modulatory network in pain and part of the basal ganglia circuitry in Parkinson's disease. Important clinical implications emerge from these recent advances in placebo research. First, as the placebo effect is basically a psychosocial context effect, these data indicate that different social stimuli, such as words and rituals of the therapeutic act, may change the chemistry and circuitry of the patient's brain. Second, the mechanisms that are activated by placebos are the same as those activated by drugs, which suggests a cognitive/affective interference with drug action. Third, if prefrontal functioning is impaired, placebo responses are reduced or totally lacking, as occurs in dementia of the Alzheimer's type. Neuropsychopharmacology Reviews (2011) 36, 339-354; doi:10.1038/npp.2010.81; published online 30 June 2010
引用
收藏
页码:339 / 354
页数:16
相关论文
共 125 条
[1]   BEHAVIORALLY CONDITIONED IMMUNOSUPPRESSION [J].
ADER, R ;
COHEN, N .
PSYCHOSOMATIC MEDICINE, 1975, 37 (04) :333-340
[2]  
ALVAR.R, 1961, ACTA PHYSIOL LAT AM, V11, P113
[3]  
ALVAREZ-BUYLLA RAMON, 1960, ACTA PHYSIOL LATINOAMER, V10, P153
[4]   Response variability to analgesics: a role for non-specific activation of endogenous opioids [J].
Amanzio, M ;
Pollo, A ;
Maggi, G ;
Benedetti, F .
PAIN, 2001, 90 (03) :205-215
[5]   Neuropharmacological dissection of placebo analgesia: Expectation-activated opioid systems versus conditioning-activated specific subsystems [J].
Amanzio, M ;
Benedetti, F .
JOURNAL OF NEUROSCIENCE, 1999, 19 (01) :484-494
[6]   Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: Behavioral and biochemical studies [J].
Andre, J ;
Zeau, B ;
Pohl, M ;
Cesselin, F ;
Benoliel, JJ ;
Becker, C .
JOURNAL OF NEUROSCIENCE, 2005, 25 (35) :7896-7904
[7]  
Bandura A., 1997, SELF EFFICACY EXERCI
[8]   ENDOGENOUS PAIN CONTROL-SYSTEMS - BRAIN-STEM SPINAL PATHWAYS AND ENDORPHIN CIRCUITRY [J].
BASBAUM, AI ;
FIELDS, HL .
ANNUAL REVIEW OF NEUROSCIENCE, 1984, 7 :309-338
[9]  
BATTERMAN RC, 1966, J NEW DRUGS, V6, P137
[10]  
BATTERMAN RC, 1968, CURR THER RES CLIN E, V10, P136